Infusyn Therapeutics is a development stage biopharmaceutical company focused on optimizing treatment for rare cardiovascular diseases (CVDs). Despite the fact that many drugs have been approved for treatment of various CVDs, it is recognized in the medical community that treatment could be significantly improved. Through the company’s lead product, we believe Infusyn Therapeutics is poised to offer a unique solution to a complex and deadly disease.
“We are thrilled with the progress of our development program and look forward to achieving our near term goal of filing an Investigational New Drug (IND) Application” stated Mike Tilton, Infusyn’s Chief Executive Officer.
James Ahern, Lucius Venture Partner added, “It is an exciting time of growth for Lucius Venture Partners. The progress of Infusyn Therapeutics is another testament to the quality of companies we continue to fund. We look forward to leveraging all of our capabilities across the LVP platform as we continue to create value for our investors in Infusyn.”